EQS-News 113 0 Kommentare Change in the Management of CHEPLAPHARM

EQS-News: Cheplapharm AG / Key word(s): Personnel
Change in the Management of CHEPLAPHARM

01.12.2022 / 10:07 CET/CEST
The issuer is solely responsible for the content of this announcement.

Patrick König leaves CHEPLAPHARM at his own request
Klaus Köhl becomes new Chief Operating Officer

Patrick König leaves the Company at the end of the year at his own request.

Patrick König has worked for CHEPLAPHARM for a total of almost five years. In 2018, the business graduate started at the pharmaceutical company specializing in well-established branded medicines as Director Global Sales. Since March 2021, as Managing Director and COO, he was initially responsible for Global Sales and Corporate Project Management, among other things, and later also for the Supply Chain division. During his tenure, CHEPLAPHARM grew into a leading international pharmaceutical platform with an annual revenue of €1.08bn.

Edeltraud Lafer, CEO of CHEPLAPHARM, thanks Patrick König for his extraordinary commitment to CHEPLAPHARM. "Patrick König has implemented numerous structural and process improvements during his time at CHEPLAPHARM, making a decisive contribution to optimizing the life cycle management of our products. We thank him for his great contributions to CHEPLAPHARM. At the same time, we respect his decision and wish him the very best for the future."

As of December 1, 2022, Klaus Köhl will assume responsibility for the operational business of CHEPLAPHARM Arzneimittel GmbH as the new Chief Operating Officer (COO).

Edeltraud Lafer is pleased to have gained an experienced industry expert in Klaus Köhl. Köhl can look back on over 17 years of professional experience in the pharmaceutical industry. In addition to many years of management experience and in-depth knowledge in the areas of supply chain, quality management, regulatory affairs, and technology transfers, as a commercial lawyer he has extensive expertise in negotiating complex, international contracts. Furthermore, Köhl brings many years of experience in the global licensing of pharmaceuticals in various therapeutic areas.

_______________________________________________________________________________________________________

About CHEPLAPHARM

CHEPLAPHARM is a fast-growing pharmaceutical company, headquartered in Greifswald, Germany, offering branded and niche products worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy.

Please refer to www.cheplapharm.com for additional information.

Press office:

CHEPLAPHARM ǀ Ziegelhof 24 ǀ 17489 Greifswald ǀ presse(at)cheplapharm.com

01.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Cheplapharm AG
	Ziegelhof 24
	17489 Greifswald
	Germany
Phone:	03834 3914 O
E-mail:	info@cheplapharm.com
Internet:	www.cheplapharm.com
ISIN:	DE000CHP2222
WKN:	CHP222
Listed:	Regulated Market in Frankfurt (Prime Standard)
EQS News ID:	1502433